中国全科医学2024，Vol.27Issue(35)：4388-4396,9.DOI:10.12114/j.issn.1007-9572.2024.0133
非苯二氮䓬类药物治疗失眠共病睡眠呼吸暂停的临床效果评价研究新进展
Advance in Evaluation of the Clinical Efficacy of Non-benzodiazepine Drugs in Treating Comorbid Insomnia and Sleep Apnea
摘要
Abstract
Comorbid insomnia and sleep apnea is a highly prevalent disorder characterized by both insomnia and sleep apnea,leading to more severe impairment of daytime function and quality of life than in patients with either insomnia or obstructive sleep apnea(OSA)alone.Non-benzodiazepine drugs(NBZDs)are frontline medications for insomnia treatment,as they can improve insomnia symptoms and enhance sleep quality.However,they are not recommended for OSA treatment due to their potential to increase the apnea-hypopnea index(AHI)and worsen the severity of sleep-disordered breathing.Currently,the therapeutic effects of NBZDs on COMISA are not well-established and require further investigation.Therefore,this article adopts a systematic review approach to compile relevant literature on the use of NBZDs in patients with OSA and COMISA,analyzing the impact of NBZDs on various indicators such as AHI,oxygen desaturation index,and sleep quality.It evaluates the clinical efficacy and safety of medications including zopiclone,eszopiclone,zolpidem,and zaleplon in the treatment of COMISA,aiming to provide guidance on the rational use of NBZDs for these patients.关键词
失眠共病睡眠呼吸暂停/佐匹克隆/右佐匹克隆/唑吡坦/扎来普隆/综述Key words
Comorbid insomnia and sleep apnea/Zopiclone/Eszopiclone/Zolpidem/Zaleplon/Review分类
医药卫生引用本文复制引用
董孟龙,林志烽,范孟孟,薛盛文,刘宇航,王怡,程金湘..非苯二氮䓬类药物治疗失眠共病睡眠呼吸暂停的临床效果评价研究新进展[J].中国全科医学,2024,27(35):4388-4396,9.基金项目
国家重点研发计划"常见多发病防治研究"专项(2021YFC2501400,2021YFC2501405) （2021YFC2501400,2021YFC2501405）
